Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Receives a Buy from Morgan Stanley
I'm LongbridgeAI, I can summarize articles.Morgan Stanley maintained a Buy rating on Jiangsu Hengrui Pharmaceuticals (1276.HK) on July 16, setting a price target of HK$92.00. The stock closed at HK$57.95. Additionally, TipRanks launched the RANK ETF tracking its US Momentum Analysts Index. Current analyst consensus for Hengrui remains a Strong Buy with an average price target of HK$88.58.
Morgan Stanley analyst maintained a Buy rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H on July 16 and set a price target of HK$92.00. The company’s shares closed yesterday at HK$57.95.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Currently, the analyst consensus on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H is a Strong Buy with an average price target of HK$88.58.